Recent Development of Multifunctional Agents as Potential Drug Candidates for the Treatment of Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 240 of the 240 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is a complex and progressive neurodegenerative disorder. The available therapy is limited to the symptomatic treatment and its efficacy remains unsatisfactory. In view of the prevalence and expected increase in the incidence of AD, the development of an effective therapy is crucial for public health. Due to the multifactorial aetiology of this disease, the multi-target-directed ligand (MTDL) approach is a promising method in search for new drugs for AD. This review updates information on the development of multifunctional potential anti-AD agents published within the last three years. The majority of the recently reported structures are acetylcholinesterase inhibitors, often endowed with some additional properties. These properties enrich the pharmacological profile of the compounds giving hope for not only symptomatic but also causal treatment of the disease. Among these advantageous properties, the most often reported are an amyloid-β antiaggregation activity, inhibition of β-secretase and monoamine oxidase, an antioxidant and metal chelating activity, NOreleasing ability and interaction with cannabinoid, NMDA or histamine H3 receptors. The majority of novel molecules possess heterodimeric structures, able to interact with multiple targets by combining different pharmacophores, original or derived from natural products or existing therapeutics (tacrine, donepezil, galantamine, memantine). Among the described compounds, several seem to be promising drug candidates, while others may serve as a valuable inspiration in the search for new effective therapies for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










































Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Chu, J., & Praticò, D. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.12.032 · Cited by 84 · cited 1×
“It has been proven that 5-lipoxygenase (5-LO) is connected with A aggregation [228, 229] and its inhibition can reduce the formation of amyloid plaques in the brain [230].”
BackgroundRetractedA new and rapid colorimetric determination of acetylcholinesterase activity
Ellman, G. L., Courtney, K. D., Andres, V., & Featherstone, R. M. (1961) · Biochemical Pharmacology · doi:10.1016/0006-2952(61)90145-9 · Cited by 27,126 · cited 1×
“The results of Ellman’s test [80] showed that the newly synthesized hybrids were EeAChE inhibitors with IC50 values in the nanomolar range, from 3.”
BackgroundThe cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545 · cited 1×
“This hypothesis assumes that in AD the level of acetylcholine (ACh) is reduced due to the loss of the cholinergic neurons and decreased synthesis of ACh [5, 6].”
BackgroundQuerfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Therapeutic potential of resveratrol: the in vivo evidence
Baur, J. A., & Sinclair, D. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2060 · Cited by 3,958 · cited 1×
“In recent years, resveratrol (3,5,4’-trihydroxystilbene) has been extensively investigated as a cardioprotective, anticancer and anti-aging compound [185-187].”
BackgroundAmyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · cited 1×
“The symptomatic therapeutic targets include mostly receptors whereas the disease-modifying targets are closely connected to A , tau production and neuroprotection [15, 16].”
BackgroundOxidative stress hypothesis in Alzheimer’s disease
Markesbery, W. R. (1997) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(96)00629-6 · Cited by 2,383
Levine, H. (1993) · Protein Science · doi:10.1002/pro.5560020312 · Cited by 2,264
DPPH antioxidant assay revisited
Sharma, O. P., & Bhat, T. K. (2009) · Food Chemistry · doi:10.1016/j.foodchem.2008.08.008 · Cited by 1,969 · cited 1×
“Interestingly, these two compounds showed an antioxidant activity in the (di(phenyl)-(2,4,6trinitrophenyl)iminoazanium) (DPPH) free radical scavenging assay [121] with IC50 values of 42.”
Background
Cited by
Copper homeostasis and cuproptosis in health and disease
Chen, L., Min, J., & Wang, F. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01229-y · Cited by 1,493
“The pathological hallmark of AD is the deposition of amyloid plaques and neurofibrillary tangles in the gray matter due to aberrant processing of amyloid precursor protein (APP) leading to the aggregation of amyloid-β (Aβ) peptides and tau protein, respectively.(91) Mounting evidence has implicated that altered Cu hom…”
BackgroundSavelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 581
Therapeutic strategies for Alzheimer's disease in clinical trials
Godyń, J., Jończyk, J., Panek, D., & Malawska, B. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2015.07.006 · Cited by 452
“New alternative approaches involve multi-target-directed ligands where a specially designed compound is able to interact with more than one biological target involved in the pathogenesis of AD [103].”
BackgroundSelf-citationSharma, P., Srivastava, P., Seth, A., Tripathi, P. N., Banerjee, A. G., & Shrivastava, S. K. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.006 · Cited by 331
VDAC1, mitochondrial dysfunction, and Alzheimer’s disease
Shoshan-Barmatz, V., Nahon-Crystal, E., Shteinfer-Kuzmine, A., & Gupta, R. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.03.010 · Cited by 286
Metadata
- Authors
- Guzior, N., Wi.eckowska, A., Panek, D., & Malawska, B.
- Affiliations
- Jagiellonian University (PL)
- Corresponding author
- Malawska, Barbara
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2014-12-19
- Volume
- 22
- Issue
- 3
- Pages
- 373-404
- ISSN
- 0929-8673 (ISSN-L)
- PMC
- PMC4435057
- OpenAlex
- W2160250661
- Cited by
- 323
- References
- 239
- Citations by year
- 2026: 10 · 2025: 10 · 2024: 20 · 2023: 24 · 2022: 28 · 2021: 29 · 2020: 26 · 2019: 40 · 2018: 46 · 2017: 41 · 2016: 36 · 2015: 12
- FWCI
- 4.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Current Medicinal Chemistry (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, other-oa)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- Funders
- Narodowym Centrum Nauki
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, multi-target-directed ligands, acetylcholinesterase inhibitors, beta-secretase inhibition, monoamine oxidase inhibition, antioxidant activity, metal chelation, nitric oxide release, cannabinoid receptors, NMDA receptor, histamine H3 receptor, tacrine, donepezil, galantamine, memantine, drug candidates
- MeSH terms
- Alzheimer Disease, Animals, Enzyme Inhibitors, Humans, Amyloid beta-Peptides, Neuroprotective Agents, Drug Discovery, Protein Aggregates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent Development of Multifunctional Agents as Potential Drug Candidates for the Treatment of Alzheimer’s Disease. https://app.cochat.ai/papers/10.2174/0929867321666141106122628
- The paper
- Guzior, N., Wi.eckowska, A., Panek, D., & Malawska, B. (2014). Recent Development of Multifunctional Agents as Potential Drug Candidates for the Treatment of Alzheimer’s Disease. Current Medicinal Chemistry. https://doi.org/10.2174/0929867321666141106122628
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.